296 related articles for article (PubMed ID: 31969559)
1. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H
Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559
[TBL] [Abstract][Full Text] [Related]
2. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
[TBL] [Abstract][Full Text] [Related]
3. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.
Han M; Gu Y; Lu P; Li J; Cao H; Li X; Qian X; Yu C; Yang Y; Yang X; Han N; Dou D; Hu J; Dong H
Mol Cancer; 2020 Feb; 19(1):26. PubMed ID: 32020881
[TBL] [Abstract][Full Text] [Related]
4. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
[TBL] [Abstract][Full Text] [Related]
5. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.
Fu R; Tong JS
J Cell Mol Med; 2020 Jul; 24(13):7600-7608. PubMed ID: 32410348
[TBL] [Abstract][Full Text] [Related]
6. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
7. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
8. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
[TBL] [Abstract][Full Text] [Related]
9. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
10. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
Liu C; Lu C; Yixi L; Hong J; Dong F; Ruan S; Hu T; Zhao X
Breast Cancer Res; 2023 Oct; 25(1):124. PubMed ID: 37848981
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
[TBL] [Abstract][Full Text] [Related]
12. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
[TBL] [Abstract][Full Text] [Related]
13. Exosome-mediated transfer of circHIPK3 promotes trastuzumab chemoresistance in breast cancer.
Zhang H; Yan C; Wang Y
J Drug Target; 2021 Nov; 29(9):1004-1015. PubMed ID: 33775192
[TBL] [Abstract][Full Text] [Related]
14. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
16. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
[TBL] [Abstract][Full Text] [Related]
17. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer.
Hermawan A; Putri H
J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
Ao X; Nie P; Wu B; Xu W; Zhang T; Wang S; Chang H; Zou Z
Cell Death Dis; 2016 Nov; 7(11):e2463. PubMed ID: 27831559
[TBL] [Abstract][Full Text] [Related]
19. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
20. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
